Share on StockTwits

Cambrex Corp. (NYSE:CBM) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research report issued on Monday. The firm currently has a $23.20 price objective on the stock. Zacks‘s price target would indicate a potential upside of 6.57% from the stock’s previous close.

A number of other firms have also recently commented on CBM. Analysts at First Analysis downgraded shares of Cambrex Corp. from an “overweight” rating to an “equal weight” rating in a research note on Friday. Analysts at Longbow Research raised their price target on shares of Cambrex Corp. to $27.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

Cambrex Corp. (NYSE:CBM) traded down 1.75% during mid-day trading on Monday, hitting $21.39. 343,545 shares of the company’s stock traded hands. Cambrex Corp. has a one year low of $12.56 and a one year high of $23.88. The stock’s 50-day moving average is $21.44 and its 200-day moving average is $20.34. The company has a market cap of $656.2 million and a price-to-earnings ratio of 20.42.

Cambrex Corp. (NYSE:CBM) last announced its earnings results on Friday, August 1st. The company reported $0.35 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.28 by $0.07. The company had revenue of $98.00 million for the quarter, compared to the consensus estimate of $92.70 million. During the same quarter in the prior year, the company posted $0.10 earnings per share. The company’s quarterly revenue was up 59.2% on a year-over-year basis. On average, analysts predict that Cambrex Corp. will post $1.11 earnings per share for the current fiscal year.

In other Cambrex Corp. news, SVP William M. Haskel sold 28,100 shares of the stock on the open market in a transaction dated Thursday, August 7th. The stock was sold at an average price of $22.50, for a total transaction of $632,250.00. The sale was disclosed in a filing with the SEC, which is available at this link.

Cambrex Corporation (NYSE:CBM) is a life sciences company, which provides products and services, which accelerate and improve the development and commercialization of new and generic therapeutics.

To view Zacks’ full report, visit Zacks’ official website.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.